Skip to content

PRE-OCC study

Pre-optimization in patients presenting with acute obstructive colon cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON26935
Enrollment
110
Registered
2020-01-06
Start date
2020-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive colon cancer

Interventions

Prosective registration of the implementation of the pre-optimization protocol in patients with obstructive colon cancer.

Sponsors

Wetenschapsacademie Amphia
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Patients 18 years or older. - Patients presenting with symptoms of bowel obstruction caused by (high suspicion or histologically proven) colonic cancer. - Patients presenting with (partial) obstruction (abdominal pain, nausea, vomiting, diarrhoea) confirmed by the presence of a dilated colon or ileum with a computed tomography (CT-scan).

Exclusion criteria

Exclusion criteria: - Obstruction of the colon pathologically caused by benign disease. - Obstruction of the colon caused by an extra-colonic malignancy. - Suspicion of emergency complications caused by peritonitis due to perforation (tumour or blow out) or sepsis. - Rectal cancer

Design outcomes

Primary

MeasureTime frame
Complication-free survival (CFS) at 90 days after hospitalization. Complication is defined here as mortality and/or development of a major complication (Clavien-Dindo classification >2).

Secondary

MeasureTime frame
Complications, creation of primary anastomosis, stoma creation, radical tumour resection, operative blood loss, operation time, total hospital stay (in total, after resection or reoperation), oncological resection. With a follow up of 1 year.

Contacts

Public ContactJeske Boeding

Amphia hospital Molengracht 21 4818 CK Breda The Netherlands

jboeding@amphia.nl0162327767

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)